Free shipping on all orders over $ 500

CEP-28122

Cat. No. M1946
CEP-28122 Structure
Size Price Availability Quantity
5mg USD 175  USD175 In stock
10mg USD 300  USD300 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation. CEP-28122 induced concentration-dependent growth inhibition/cytotoxicity of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice. CEP-28122 displayed marginal antitumor activity against ALK-negative human tumor xenografts under the same dosing regimens. Administration of CEP-28122 was well tolerated in mice and rats. In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacologic efficacy against ALK-positive human cancer cells and tumor xenograft models in mice.

Customer Product Validations & Biological Datas
Source Mol Cancer Ther (2012). Figure 2. CEP-28122
Method MTS assays
Cell Lines NPM-ALK–positive ALCL (Karpas-299 and Sup-M2) cells
Concentrations 30, 100, 300 and 1,000 nmol/L
Incubation Time 48 h
Results The activity of growth inhibition and caspase activation are consistent with the cellular inhibition of NPM-ALK phosphorylation. In contrast, CEP-28122 had no-to-marginal growth inhibition and did not induce significant caspase 3/7 activation in ALK-negative leukemia Toledo and lymphoma HuT-102 cells at concentrations up to 3,000 nmol/L
Source Mol Cancer Ther (2012). Figure 1. CEP-28122
Method immunoblot analysis
Cell Lines NSCLC NCI-H2228 and NCI-H3122 cells
Concentrations 30, 100, 300 and 1,000 nmol/L
Incubation Time 2 h
Results In a cellular phosphorylation assay, treatment of NPMALK–positive ALCL cells, Sup-M2 and Karpas-299, with CEP-28122 led to concentration-related inhibition of NPM-ALK tyrosine (664) phosphorylation, with calculated cellular IC50 values of 20 to 30 nmol/L
Protocol (for reference only)
Cell Experiment
Cell lines NPM-ALK–positive ALCL (Karpas-299 and Sup-M2) cells and ALK-negative lymphoma HuT-102 and leukemia Toledo cells; EML4-ALK–positive (NCI-H2228 and H3122) and EML4-ALK–negative (NCI-H1650) NSCLC cells and neuroblastoma cell lines
Preparation method Cell growth inhibition
Living cells were measured with the CellTiter 96 nonradioactive cell proliferation assay (MTS assay) kit. In brief, the cells were seeded on 96-well plates and 48 to 72 hours after compound treatment, equal volume of reagents from the kit was added to the culture medium. After incubation for 1 to 4 hours, the plates were measured with a plate reader and the relative cell numbers were calculated on the basis of the standard curve.
Concentrations 0~10 μ M
Incubation time 48 to 72 h
Animal Experiment
Animal models SCID mice bearing NCI-H2228, NCI-H3122, and NCI-1650 (A) or NB-1 and NB-1691 (B) subcutaneous tumor xenografts
Formulation PEG-400, or dH2O
Dosages 3, 10, or 30 mg/kg twice a day for 10 days
Administration oral
Chemical Information
Molecular Weight 539.07
Formula C28H35ClN6O3
CAS Number 1022958-60-6
Solubility (25°C) DMF: 10 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Cheng M, et al. Mol Cancer Ther. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Related ALK Products
NVL-655

NVL-655 is a novel, brain-permeable, selective ALK inhibitor with antitumor activity. For Ba/F3 CLIP1-LTK cells, NVL-655 has an IC50 of 2.7 nM. It can be used in studies related to ALK-positive non-small cell lung cancer (NSCLC).

APG-2449

APG-2449 is an orally active, potent ALK/ROS1/FAK inhibitor with anti-tumor activity in a mouse model of non-small cell lung cancer (NSCLC).

ALK2-IN-5

ALK2-IN-5, pyrazolopyrimidine compound, is an ALK2 inhibitor.

J-1048

J-1048 is an activin receptor-like kinase 5 (ALK5) inhibitor.

CPD-1224

CPD-1224 is an orally active derivative of ALK inhibitors to cereblon ligands.

  Catalog
Abmole Inhibitor Catalog




Keywords: CEP-28122 supplier, ALK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.